How OCA fits the cartilage repair pathway

For patients with a large area of missing cartilage and damaged bone beneath it, most standard repair techniques reach their limits — and that is precisely where osteochondral allograft (OCA) transplantation becomes relevant. In a single procedure, a surgeon replaces the damaged osteochondral unit with a fresh plug of donor cartilage and the supporting bone underneath it, restoring the joint surface in one stage rather than two.

OCA sits at the third stage of the cartilage care pathway. Most patients will have worked through symptom management and, in many cases, biologic or scaffold support before reaching this point. OCA is not an early-intervention option; it is a joint-preservation option — the goal being to delay or avoid knee replacement in a patient who is too young or too active for arthroplasty.

What distinguishes it from cell-based procedures such as MACI or ACI is the inclusion of the bony scaffold. Where bone loss is present — as it commonly is after trauma or osteochondritis dissecans — rebuilding cartilage cells alone is insufficient. OCA addresses both layers at once.

NHS commissioning expanded in October 2022, opening a formal NHS route for eligible patients; that landscape is covered in detail in a later section.

Who is a candidate for OCA

Three factors, considered together, determine whether a patient is likely to benefit from OCA: the size and severity of the defect, the individual's age and joint status, and the origin of the damage.

Defect size and grade

OCA is designed for focal, full-thickness lesions classified as ICRS Grade 3 or 4 — meaning the damage reaches or passes through the cartilage layer into the subchondral bone beneath. The threshold for considering OCA typically begins at around 2–4 cm², where smaller single-stage autograft options such as OATS start to become insufficient. Once a lesion exceeds approximately 6 cm², OCA is often the only realistic single-stage restorative option: at that scale, the volume of bony scaffold required cannot be sourced from the patient's own tissue.

Patient profile

Candidates are generally skeletally mature and under 40–50 years old — active enough to justify preservation rather than replacement, but not yet at a stage where arthroplasty is the natural next step. Equally important is what the joint does not have: multi-compartment osteoarthritis, ligament instability, or a significant malalignment that would load the graft unevenly. Conservative management — physiotherapy, activity modification, and in many cases biologic or injection-based support — must have been tried and found insufficient before OCA is considered.

Why the cause of the defect matters

Post-traumatic lesions — those arising from intra-articular fractures or high-energy impacts — carry a materially better prognosis for graft integration than defects driven by degenerative change. Osteochondritis dissecans (OCD), a condition in which a segment of bone and cartilage separates from the joint surface, is another common qualifying aetiology with generally favourable outcomes. Patients with primarily degenerative lesions are not automatically excluded, but the evidence for graft survival is less robust, and a consultant assessment is needed to weigh the individual risk carefully.

Diffuse or multi-compartment osteoarthritis sits outside the scope of OCA — the procedure depends on an otherwise preserved joint environment to support the graft.

NHS access after the 2022 commissioning change

October 2022 brought a meaningful change for patients who might need OCA but cannot afford to fund it privately. NHS England formally adopted a Clinical Commissioning Policy designating fresh OCA as a Group D specialised service — meaning eligible adults and post-pubescent children can now be referred through the standard NHS specialist pathway without needing an individual funding request. Before this change, many patients faced an uncertain, case-by-case application process that added months to an already long road.

The policy was supported by a 2019 health-economics study led by researchers at the University of Warwick (Mistry et al.), which modelled OCA against other established NHS treatments and found the cost per quality-adjusted life year to be highly favourable. That analysis, alongside the clinical evidence, gave commissioners sufficient confidence to move OCA into routine commissioning. The University Hospitals Coventry and Warwickshire NHS Trust — where one of the UK's highest-volume OCA practices operates — contributed substantially to the real-world evidence base that informed this decision.

In practice, NHS access is not uniform. Waiting times, referral pathways, and the availability of high-volume surgical teams vary between trusts and regions. Patients in areas without an established OCA programme may face longer waits or onward referral to a specialist centre.

For patients who need greater certainty on timing, or whose local NHS pathway is not straightforward, private assessment offers a consistent route — typically without a GP referral requirement and without the variability of NHS waiting lists.

Private OCA costs in the UK

The clearest publicly available benchmark for private OCA in the UK comes from London Cartilage Clinic, which lists the procedure at £28,000 all-inclusive. That figure covers donor osteochondral tissue, theatre costs, the consultant anaesthetist, surgical disposables, and a twelve-month follow-up programme — meaning patients are not expected to budget separately for any of those components once the procedure is confirmed.

For patients with defects small enough to be treated with an autograft, OATS is available at £14,000 — roughly half the cost of OCA, and a meaningful difference for anyone deciding between the two pathways on financial as well as clinical grounds.

Beyond those published figures, the pricing landscape becomes harder to navigate. Private OCA costs are not consistently published across UK providers. Because the procedure is niche and involves logistically complex fresh-tissue procurement, most clinics quote on a case-by-case basis. That creates a real comparison problem: two quotes from different providers may cover very different things. Patients comparing costs should ask specifically whether any quoted figure includes donor tissue acquisition, theatre fees, the anaesthetist, and post-operative follow-up — or whether those are billed as separate line items.

The cost reflects the nature of the procedure itself. Fresh osteochondral grafts must be procured, processed, tissue-matched, and transplanted within a tight viability window; unlike standard orthopaedic implants, they cannot be stocked off the shelf. Specialist surgical expertise in high-volume OCA adds a further component that is not replicated widely across the country.

For patients outside London, MSK Doctors can provide a clear account of what any assessment or treatment pathway would involve — bookable directly at mskdoctors.com without a GP referral.

Recovery after OCA surgery

The splint comes off at around two weeks — but that is only the start of a staged return to normal life that takes the best part of a year.

Weeks 0–8: protecting the graft

For the first six to eight weeks, the priority is controlled offloading. Patients are partial weight bearing on crutches, gradually increasing load under physiotherapy supervision as the graft begins to integrate. The splint is removed at approximately two weeks, but the joint itself needs considerably longer before it can bear full body weight.

Weeks 8–12: resuming full weight bearing

Full weight bearing is typically achieved between eight and twelve weeks. This is a milestone, not a return to activity — the graft is still maturing, and the rehabilitation programme shifts to restoring range of motion and rebuilding the muscle support around the joint.

Months 4–6: low-impact activity

Swimming and stationary cycling are generally introduced from around four to six months, once the joint tolerates controlled movement without significant swelling. Walking distances extend progressively through this phase.

Months 6–12+: return to sport

A return to high-impact sport takes a mean of 11.1 months, based on a 2025 systematic review of 471 athletes. Seventy-two per cent returned to sport — a majority, but not a given — and of those, 84% did so at an equal or higher level than before surgery. These figures reflect realistic probabilities, not guaranteed outcomes.

Throughout every phase, supervised rehabilitation is essential. The graft cannot be protected by rest alone; structured physiotherapy determines whether the tissue integrates successfully and whether the surrounding joint recovers its full function. This is not a self-directed recovery.

Long-term graft survival and what the evidence shows

Survival data for OCA divides cleanly by lesion complexity — a distinction patients should understand before surgery.

For isolated focal defects, the long-term picture is genuinely encouraging: graft survival exceeds 90% at ten years, with approximately 70% of grafts remaining functional at 20–25 years post-surgery. These figures sit behind the cost-effectiveness case described in the NHS commissioning section above.

For bipolar lesions — where damage is present on opposing joint surfaces — the outlook is materially different. In a cohort of 86 patients with a mean age of 37.9 years, survivorship was 73.8% at five years, falling to 66.6% at ten years and 58.9% at fifteen, with a mean time to graft failure of 4.8 years. Patients with complex bipolar disease should receive these figures clearly, not filtered through the more favourable isolated-defect numbers.

Two variables that tend to concern patients — donor-recipient sex mismatch and the time tissue has spent in storage — do not appear to materially affect outcomes once patient sex is controlled, a reassuring finding for those worried about graft compatibility. Early evidence also suggests that augmenting the procedure with bone marrow aspirate concentrate (BMAC) may reduce reoperation rates substantially, though this remains an emerging adjunct rather than an established standard of care.

Understanding which category applies — isolated or complex — is a central part of any pre-surgical assessment; the MSK Doctors team accepts direct bookings without a referral at mskdoctors.com.

OCA is a joint-preserving strategy, not a permanent solution. If the graft eventually reaches the end of its useful life, joint replacement remains available — and OCA does not close that door.

1. [1] Optimizing Patient Outcomes Following Osteochondral Allograft Transplantation: 25 Years of Research. (2025). https://doi.org/10.1002/jor.26089 https://doi.org/10.1002/jor.26089
2. [2] Midterm Survivorship in Fresh OCA Transplantation for Large Bipolar Lesions of the Knee. (2025). https://doi.org/10.1177/03635465241313139 https://doi.org/10.1177/03635465241313139
3. [3] Return to Sport in Athletes After Osteochondral Allograft Transplantation: A Systematic Review. (2025). https://doi.org/10.1177/03635465251315492 https://doi.org/10.1177/03635465251315492